n n n ‘. concat(e. i18n. t(“search. voice. recognition_retry”),’n
DALLAS and TORONTO, Oct. 31, 2023 /PRNewswire/ — Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (ESF: 4PC) (“Perimeter” or the “Company”): A Commercial-Stage Medical Generation Corporate – announced the launch of another clinical trial site at the University of Washington’s Fred Hutch Cancer Center in Seattle, WA.
Perimeter Institute is recently conducting a multicenter, randomized, two-arm, pivotal trial comparing the experimental Perimeter B-Series OCT combined with its proprietary ImgAssist AI software when used in breast-sparing surgical procedures.
Meghan R. Flanagan, MD, MPD, University of Washington/Fred Hutch Cancer Center, said, “Recognizing the unmet desire in the field of breast cancer margin visualization, we are pleased to have the latest site to participate in this clinical trial. “With high-resolution imaging, he has the prospect of a new trend in the care of breast-conserving surgeries, reducing the number of repeat surgeries and ultimately delivering better outcomes for patients. “
Adrian Mendes, President and CEO of Perimeter Institute, said, “We are working to drive the progression of our next-generation AI generation and its clinical evaluation in an ongoing pivotal trial. We hope that the knowledge generated through this study will be used for commercialization. “of Perimeter Institute. B-Series, which is our purpose to transform cancer surgery by delivering a generation that improves patient outcomes and reduces health care costs. “
About Perimeter Medical Imaging AI, Inc.
Headquartered in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSX-V: PINK) (OTC: PYNKF) (FSE: 4PC) is a medical-generation company whose goal is to transform cancer surgery with true-to-life, ultra-high-resolution imaging. global technologies. Complex imaging equipment and time to deal with spaces where medical desires are significant and unsatisfied. Available in the U. S. , our FDA-approved OCT Perimeter S-Series formula allows for real-time cross-sectional visualization of excised tissue at the cellular level. The Perimeter B-Series experimental OCT with ImgAssist AI, referred to as the breakthrough device, represents our generation of next-generation synthetic intelligence that is ultimately being evaluated in a pivotal clinical trial, supported through a grant of up to $7. 4 million from Cancer Prevention. The company’s inventory symbol “PINK” refers to the pink ribbons used in Breast Cancer Awareness Month.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This press release contains statements that constitute “forward-looking information” within the meaning of applicable Canadian securities legislation. In this press release, words such as “possibly”, “could”, “may also”, “will”, “likely”, “believe”, “expect”, “anticipate”, “intend”, “plans”, “estimates” and similar words and their negative form are used to identify forward-looking statements. Forward-looking information would possibly relate to management’s long-term clients and expected events or effects and would possibly come with statements or information related to the long-term . execute monetary condition, business strategy and strategic objectives, competitive conditions, studies and progression activities, projected prices and capital expenditures, studies and clinical activities, control effects, taxes, the plans and objectives of or involving Perimeter the benefits of OCT Perimeter S-Series, OCT Perimeter B-Series and Perimeter ImgAssist the main points related to ongoing clinical trials at Perimeter Institute; and the expected final date of Perimeter Institute’s clinical trials are a vision of the future. Forward-looking statements should not be construed as promises of long-term results or effects and will not necessarily constitute express indications of whether, when or by what means a specific result will be achieved. No assurance can be given that the events expected in the forward-looking setting will or will occur. Prospective nonconformity is based on current nonconformity and/or management’s intelligent religious belief regarding long-term events and is subject to known or unknown risks, uncertainties, assumptions and other unpredictable factors. and many of them are beyond the perimeter. Institute. Array These forward-looking statements reflect Perimeter Institute’s existing views with respect to long-term events, but are inherently subject to significant medical, scientific, business, economic, competitive, political and social uncertainties and contingencies. In making forward-looking statements, Perimeter may make various assumptions, including, among others, (i) the accuracy of Perimeter’s monetary projections; (ii) download positive check effects; (iii) download mandatory regulatory approvals; and (iv) general business, market and economic conditions. Other risks, uncertainties and assumptions come with, among others, those applicable to Perimeter Institute and described in Perimeter Institute’s MD&A for the year ended December 31, 2022, which can be obtained on Perimeter Institute’s SEDAR profile at www. sedate . com, and may also cause actual events or effects to differ materially from those projected in the forward-looking statements. Perimeter has no intention, nor undertakes any obligation, to update or revise any forward-looking settings contained in this press release to reflect upcoming settings, occasions or cases or otherwise, unless required by law. The applicable regulations require it.
Show content: https://www. prnewswire. com/news-releases/perimeter-medical-imaging-ai-announces-initiation-of-new-clinical-trial-site-at-university-of-washingtonfred-hutch-cancer -centro-301972099. html
SOURCE Perimeter Medical Imaging, Inc.
View content: http://www. newswire. ca/en/releases/archive/October2023/31/c9543. html